144 related articles for article (PubMed ID: 36843539)
1. Aberrant p53 Expression in Gastric Biopsies and Resection Specimens Following Neoadjuvant Chemoradiation: A Diagnostic Pitfall.
Hutchings DA; Salimian KJ; Waters KM; Birkness-Gartman JE; Voltaggio L; Assarzadegan N; Huang J; Lin MT; Singhi AD; Montgomery EA
Int J Surg Pathol; 2023 Dec; 31(8):1458-1465. PubMed ID: 36843539
[TBL] [Abstract][Full Text] [Related]
2. Gastric dysplasia-like epithelial atypia associated with chemoradiotherapy for esophageal cancer: a clinicopathologic and immunohistochemical study of 15 cases.
Brien TP; Farraye FA; Odze RD
Mod Pathol; 2001 May; 14(5):389-96. PubMed ID: 11353047
[TBL] [Abstract][Full Text] [Related]
3. Expression of p53-related protein p63 in the gastrointestinal tract and in esophageal metaplastic and neoplastic disorders.
Glickman JN; Yang A; Shahsafaei A; McKeon F; Odze RD
Hum Pathol; 2001 Nov; 32(11):1157-65. PubMed ID: 11727253
[TBL] [Abstract][Full Text] [Related]
4. Clinical significance of the immunohistochemical detection of p53 protein in endoscopic biopsy specimens.
Jiang H; Han P; Jiang Y; Liang X; Hu C; Yang D
Chin Med J (Engl); 1997 Mar; 110(3):202-5. PubMed ID: 9594341
[TBL] [Abstract][Full Text] [Related]
5. Detection of p53 nuclear protein accumulation in brushings and biopsies of Barrett's esophagus.
Tsai TT; Bongiorno PF; Orringer MB; Beer DG
Cancer Detect Prev; 1997; 21(4):326-31. PubMed ID: 9232323
[TBL] [Abstract][Full Text] [Related]
6. Patterns of p53 immunoreactivity in non-neoplastic and neoplastic Barrett's mucosa of the oesophagus: in-depth evaluation in endoscopic mucosal resections.
Toon C; Allanson B; Leslie C; Acott N; Mirzai B; Raftopoulos S; Kumarasinghe MP
Pathology; 2019 Apr; 51(3):253-260. PubMed ID: 30826014
[TBL] [Abstract][Full Text] [Related]
7. [Predictive value of P53, Ki-67, HER2 protein detection in neoadjuvant chemotherapy for adenocarcinoma of gastroesophageal junction].
Li S; Li J; Liu Z; Zhang Z; Zhang W; Yang H; Li B
Zhonghua Wei Chang Wai Ke Za Zhi; 2015 Sep; 18(9):901-4. PubMed ID: 26404687
[TBL] [Abstract][Full Text] [Related]
8. P53 and SOX2 Protein Expression Predicts Esophageal Adenocarcinoma in Response to Neoadjuvant Chemoradiotherapy.
van Olphen SH; Biermann K; Shapiro J; Wijnhoven BP; Toxopeus EL; van der Gaast A; Stoop HA; van Lanschot JJ; Spaander MC; Bruno MJ; Looijenga LH
Ann Surg; 2017 Feb; 265(2):347-355. PubMed ID: 28059963
[TBL] [Abstract][Full Text] [Related]
9. AGA Clinical Practice Update on Endoscopic Treatment of Barrett's Esophagus With Dysplasia and/or Early Cancer: Expert Review.
Sharma P; Shaheen NJ; Katzka D; Bergman JJGHM
Gastroenterology; 2020 Feb; 158(3):760-769. PubMed ID: 31730766
[TBL] [Abstract][Full Text] [Related]
10. Use of Immunohistochemical p53 Mutant-Phenotype in Diagnosis of High-Grade Dysplasia of Esophageal Squamous Epithelia.
Xu YJ; Li R; Chen JM; Zhuang XY; Lin N; Wang LP; Zeng BW
Dig Dis; 2023; 41(5):685-694. PubMed ID: 37579733
[TBL] [Abstract][Full Text] [Related]
11. Apoptotic and proliferative indexes in esophageal cancer: predictors of response to neoadjuvant therapy [corrected].
Beardsmore DM; Verbeke CS; Davies CL; Guillou PJ; Clark GW
J Gastrointest Surg; 2003 Jan; 7(1):77-86; discussion 86-7. PubMed ID: 12559188
[TBL] [Abstract][Full Text] [Related]
12. Detecting p53 immunoexpression in esophageal mucosa with exfoliative cytology in individuals at risk for squamous cell carcinoma of the esophagus.
Lopes AB; Müller LB; Reichert R; Moraes CM; Capra AM; Prolla JC; Diehl AR; Meurer L; de Barros SG; Fagundes RB
Acta Cytol; 2010; 54(1):31-8. PubMed ID: 20306985
[TBL] [Abstract][Full Text] [Related]
13. Morphologic effects of neoadjuvant chemotherapy in locally advanced breast cancer.
Moll UM; Chumas J
Pathol Res Pract; 1997; 193(3):187-96. PubMed ID: 9198104
[TBL] [Abstract][Full Text] [Related]
14. Differential diagnosis of atypical epithelium of biopsied gastric mucosa using immunostaining of Ki-67, p53, hMLH1 and MDM2 expression.
Ito E; Saito K; Takizawa T; Koike M
J Exp Clin Cancer Res; 2002 Dec; 21(4):527-37. PubMed ID: 12636099
[TBL] [Abstract][Full Text] [Related]
15. Expression of cell cycle regulatory proteins in the multistep process of oesophageal carcinogenesis: stepwise over-expression of cyclin E and p53, reduction of p21(WAF1/CIP1) and dysregulation of cyclin D1 and p27(KIP1).
Ohbu M; Kobayashi N; Okayasu I
Histopathology; 2001 Dec; 39(6):589-96. PubMed ID: 11903577
[TBL] [Abstract][Full Text] [Related]
16. p53 immunoreactivity in Barrett's metaplasia, dysplasia, and carcinoma.
Rice TW; Goldblum JR; Falk GW; Tubbs RR; Kirby TJ; Casey G
J Thorac Cardiovasc Surg; 1994 Dec; 108(6):1132-7. PubMed ID: 7983883
[TBL] [Abstract][Full Text] [Related]
17. Effect of neoadjuvant chemoradiotherapy on p53 and SOX2 protein expression in esophageal adenocarcinoma.
Suzuki L; Nieboer D; van Lanschot JJ; Spaander MC; Looijenga LH; Biermann K
Biomark Med; 2020 Jun; 14(9):785-793. PubMed ID: 32677456
[No Abstract] [Full Text] [Related]
18. Alterations of p53 and PCNA in cancer and adjacent tissues from concurrent carcinomas of the esophagus and gastric cardia in the same patient in Linzhou, a high incidence area for esophageal cancer in northern China.
Chen H; Wang LD; Guo M; Gao SG; Guo HQ; Fan ZM; Li JL
World J Gastroenterol; 2003 Jan; 9(1):16-21. PubMed ID: 12508343
[TBL] [Abstract][Full Text] [Related]
19. p53 status and prognosis of locally advanced prostatic adenocarcinoma: a study based on RTOG 8610.
Grignon DJ; Caplan R; Sarkar FH; Lawton CA; Hammond EH; Pilepich MV; Forman JD; Mesic J; Fu KK; Abrams RA; Pajak TF; Shipley WU; Cox JD
J Natl Cancer Inst; 1997 Jan; 89(2):158-65. PubMed ID: 8998185
[TBL] [Abstract][Full Text] [Related]
20. Expression of p53 protein in normal, dysplastic, and malignant gastric mucosa: an immunohistochemical study.
Joypaul BV; Newman EL; Hopwood D; Grant A; Qureshi S; Lane DP; Cuschieri A
J Pathol; 1993 Jul; 170(3):279-83. PubMed ID: 8133401
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
